Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Stein, M. B. Articles by Matloff, J. L. Search for Related Content PubMed Citation Articles by Stein, M. B. Articles by Matloff, J. L. Posttraumatic Stress Disorder Other Patient Groups/Issues Antidepressants Atypical Neuroleptics

Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: A Double-Blind, Placebo-Controlled Study

OBJECTIVE: Posttraumatic stress disorder (PTSD), particularly in combat veterans with chronic illness, is often refractory to standard pharmacological interventions. There is a need to test adjunctive treatments to boost response. METHOD: Subjects were 19 patients with PTSD who were minimally responsive to 12 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI) at maximum tolerated dose. Outcomes were compared among subjects whose treatment was augmented with 8 weeks of double-blind olanzapine or placebo administration. RESULTS: Olanzapine augmentation was associated with statistically significantly greater reduction than placebo in specific measures of posttraumatic stress, depressive, and sleep disorder symptoms. Clinician-rated global response rates did not, however, significantly differ between groups. CONCLUSIONS: This is most likely the first double-blind, placebo-controlled study of an adjunct to SSRIs for PTSD. Despite the small group size, the findings suggest a role for olanzapine or other atypical antipsychotics in treating SSRI-resistant PTSD. Sleep symptoms may especially benefit.

This article has been cited by other articles:

				J. I. Bisson Pharmacological treatment of post-traumatic stress disorder Advan. Psychiatr. Treat., March 1, 2007; 13(2): 119 - 126. [Abstract] [Full Text] [PDF]

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				C.-Y. Wang, Z.-J. Zhang,, W.-B. Li, Y.-M. Zhai, Z.-J. Cai, Y.-Z. Weng, R.-H. Zhu, J.-P. Zhao, and H.-H. Zhou The Differential Effects of Steady-State Fluvoxamine on the Pharmacokinetics of Olanzapine and Clozapine in Healthy Volunteers J. Clin. Pharmacol., July 1, 2004; 44(7): 785 - 792. [Abstract] [Full Text] [PDF]

				F. B. Schoenfeld, C. R. Marmar, and T. C. Neylan Current Concepts in Pharmacotherapy for Posttraumatic Stress Disorder Psychiatr Serv, May 1, 2004; 55(5): 519 - 531. [Abstract] [Full Text] [PDF]

				T. A. Mellman, R. E. Clark, and W. J. Peacock Prescribing Patterns for Patients With Posttraumatic Stress Disorder Psychiatr Serv, December 1, 2003; 54(12): 1618 - 1621. [Abstract] [Full Text] [PDF]

				K. M. Connor and M. I. Butterfield Posttraumatic Stress Disorder Focus, July 1, 2003; 1(3): 247 - 262. [Abstract] [Full Text] [PDF]

				A. K. JAINER and M. CHAWLA Randomized Controlled Trials Am J Psychiatry, June 1, 2003; 160(6): 1189 - 1190. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us